Quest PharmaTech Inc

Research Quest PharmaTech Inc (QPT) on Bullrun: market cap CAD 5.07M, P/E 0.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CAD 5.07M; P/E is 0.8.

Peer valuation comparison

Latest P/E is 0.83x versus a Healthcare sector median of 24.46x (96.6% below).

Latest P/E is 0.83x versus a Canada median of 15.58x (94.7% below).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-14CAD 5.07M0.8n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 CAD.

About Quest PharmaTech Inc

Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Quest PharmaTech Inc's market cap?

Quest PharmaTech Inc's market capitalization is CAD 5.07M.

What is Quest PharmaTech Inc's P/E ratio?

Quest PharmaTech Inc's price-to-earnings (P/E) ratio is 0.8.

What does Quest PharmaTech Inc do?

Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.